(Q28262497)

https://api.crossref.org/works/10.1177%2F0091270005277935

Clinical pharmacokinetics and pharmacodynamics of selegiline. An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Oxidative stress and the pathogenesis of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Selective acetylenic 'suicide' and reversible inhibitors of monoamine oxidase types A and B

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Tyramine antagonistic properties of AGN 1135, an irreversible inhibitor of monoamine oxidase type B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Platelet monoamine oxidase B: use and misuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Metabolism of selegiline hydrochloride, a selective monoamine b-type inhibitor, in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Comparative studies on the cytochrome p450-associated metabolism and interaction potential of selegiline between human liver-derived in vitro systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Pharmacological comparison between the actions of methamphetamine and 1-aminoindan stereoisomers on sympathetic nervous function in rat vas deferens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Precursor medications as a source of methamphetamine and/or amphetamine positive drug testing results

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Levodopa and the progression of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Adverse drug reactions to selegiline: a review of the French pharmacovigilance database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Rasagiline enhances L-DOPA-induced contralateral turning in the unilateral 6-hydroxydopamine-lesioned guinea-pig

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Safety of selegiline with cold medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Severe adverse interaction between pethidine and selegiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. Parkinson Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Neuroprotective actions of selegiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Modulation of gene expression rather than monoamine oxidase inhibition: (-)-deprenyl-related compounds in controlling neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Characterization of the neuroprotective activity of rasagiline in cerebellar granule cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

The essentiality of Bcl-2, PKC and proteasome–ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Rasagiline and its (S) enantiomer increase survival and prevent stroke in salt-loaded stroke-prone spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935

Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270005277935